Tamoxifen Ameliorates Peritoneal Membrane Damage by Blocking Mesothelial to Mesenchymal Transition in Peritoneal Dialysis
暂无分享,去创建一个
R. Selgas | M. Bajo | Rafael Selgas | A. Aguilera | J. Sánchez-Toméro | José Antonio Sánchez-Tomero | Jesús Loureiro | Pilar Sandoval | Gloria del Peso | Guadalupe Gónzalez-Mateo | Vanessa Fernández-Millara | Beatríz Santamaria | Maria Auxiliadora Bajo | Gonzalo Guerra-Azcona | Manuel López-Cabrera | Abelardo I. Aguilera | B. Santamaria | G. del Peso | M. López-Cabrera | P. Sandoval | J. Loureiro | G. Gónzalez-Mateo | Vanessa Fernández-Míllara | Gonzalo Guerra-Azcona | G. Del Peso | Pilar Sandoval
[1] J. Darbon,et al. Opposite effects of tamoxifen on in vitro protein kinase C activity and endogenous protein phosphorylation in intact MCF-7 cells. , 1990, Cancer research.
[2] J. Preskitt,et al. The response of retroperitoneal fibrosis to tamoxifen. , 1991, Surgery.
[3] Y. Kawaguchi,et al. Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[4] D. Grainger,et al. Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice. , 1997, Circulation.
[5] C. Labrie,et al. Morphological changes induced by 6-month treatment of intact and ovariectomized mice with tamoxifen and the pure antiestrogen EM-800. , 1997, Endocrinology.
[6] S. Inoue,et al. Estrogens stimulate tamoxifen-induced neuronal cell apoptosis in vitro: a possible nongenomic action. , 1997, Biochemical and biophysical research communications.
[7] I. Pisoni,et al. Continuous ambulatory peritoneal dialysis and sclerosing encapsulating peritonitis: tamoxifen as a new therapeutic agent? , 1999, Journal of nephrology.
[8] A. C. van der Wal,et al. Neoangiogenesis in the Peritoneal Membrane , 2000, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.
[9] R. Selgas,et al. Managing Ultrafiltration Failure by Peritoneal Resting , 2000, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.
[10] M. Dewhirst,et al. Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] S. Barsky,et al. Tamoxifen enhances myoepithelial cell suppression of human breast carcinoma progression in vitro by two different effector mechanisms. , 2000, Cancer letters.
[12] T. Peretz,et al. Synergistic inhibitory effects of genistein and tamoxifen on human dysplastic and malignant epithelial breast cells in vitro. , 2002, European journal of obstetrics, gynecology, and reproductive biology.
[13] V. Jordan,et al. Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention. , 2002, Trends in molecular medicine.
[14] Alberto Ortiz,et al. Intracellular mechanisms of cyclosporin A-induced tubular cell apoptosis. , 2003, Journal of the American Society of Nephrology : JASN.
[15] J. Jimenez-Heffernan,et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. , 2003, The New England journal of medicine.
[16] R. Selgas,et al. Clinical experience with tamoxifen in peritoneal fibrosing syndromes. , 2003, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.
[17] P. Bonniaud,et al. Basic Mechanisms and Clinical Implications of Peritoneal Fibrosis , 2003, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.
[18] A. Yang,et al. Myofibroblastic conversion of mesothelial cells. , 2003, Kidney international.
[19] S. Mandlekar,et al. Mechanisms of tamoxifen-induced apoptosis , 2001, Apoptosis.
[20] R. L. Richardson,et al. Adipose tissue angiogenesis. , 2004, Journal of animal science.
[21] M. Yáñez-Mó,et al. Epithelial to mesenchymal transition as a triggering factor of peritoneal membrane fibrosis and angiogenesis in peritoneal dialysis patients. , 2005, Current opinion in investigational drugs.
[22] H. Nagai,et al. Plasma Leptin Concentration in Tamoxifen-Treated Ovariectomized Rats , 2005, Gynecologic and Obstetric Investigation.
[23] J. Jimenez-Heffernan,et al. Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[24] H. Kawanishi. The Pathogenesis and Therapeutic Option of Encapsulating Peritoneal Sclerosis , 2005, The International journal of artificial organs.
[25] S. Altunyurt,et al. Raloxifene increases serum leptin levels in postmenopausal women: a prospective study. , 2005, American journal of obstetrics and gynecology.
[26] K. Lai,et al. Leptin induces TGF-beta synthesis through functional leptin receptor expressed by human peritoneal mesothelial cell. , 2006, Kidney international.
[27] I. Lambrinoudaki,et al. The Cardiovascular Effects of Selective Estrogen Receptor Modulators , 2006, Annals of the New York Academy of Sciences.
[28] J. Jimenez-Heffernan,et al. Ex Vivo Analysis of Dialysis Effluent-Derived Mesothelial Cells as an Approach to Unveiling the Mechanism of Peritoneal Membrane Failure , 2006, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.
[29] A. Yang,et al. Leptin augments myofibroblastic conversion and fibrogenic activity of human peritoneal mesothelial cells: a functional implication for peritoneal fibrosis. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[30] J. Jimenez-Heffernan,et al. Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. , 2007, Journal of the American Society of Nephrology : JASN.
[31] D. Brann,et al. Neuroprotective effects of estrogen and tamoxifen in vitro , 2003, Endocrine.
[32] T. Ludwig,et al. Disruption of peripheral leptin signaling in mice results in hyperleptinemia without associated metabolic abnormalities. , 2007, Endocrinology.
[33] A. Cerezo,et al. Epithelial-to-mesenchymal transition of peritoneal mesothelial cells is regulated by an ERK/NF-κB/Snail1 pathway , 2008, Disease Models & Mechanisms.
[34] J. Jimenez-Heffernan,et al. Epithelial-to-mesenchymal transition of mesothelial cells is an early event during peritoneal dialysis and is associated with high peritoneal transport. , 2008, Kidney international. Supplement.
[35] A. Davenport,et al. The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[36] Pilar Martín,et al. PPAR-γ agonist rosiglitazone protects peritoneal membrane from dialysis fluid-induced damage , 2010, Laboratory Investigation.
[37] O. Devuyst,et al. The pathophysiology of the peritoneal membrane. , 2010, Journal of the American Society of Nephrology : JASN.
[38] S. Fox,et al. Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients , 2010, Breast Cancer Research and Treatment.
[39] S. Barsky,et al. ERα signaling through slug regulates E-cadherin and EMT , 2010, Oncogene.
[40] Hester F. Lingsma,et al. Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[41] R. Selgas,et al. Blocking TGF-β1 protects the peritoneal membrane from dialysate-induced damage. , 2011, Journal of the American Society of Nephrology : JASN.
[42] C. Yen,et al. Tamoxifen Downregulates Connective Tissue Growth Factor to Ameliorate Peritoneal Fibrosis , 2011, Blood Purification.
[43] J. Vieira,et al. Antifibrotic effect of tamoxifen in a model of progressive renal disease. , 2012, Journal of the American Society of Nephrology : JASN.